Position
Fidelity in CytomX Therapeutics, Inc.
Back to the book · All holders of CTMX
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark −$30.4M$4.70 → $3.75
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 24.7M | $105.2M | — | — | — | 0.0% |
| Q1 2026 | 32M | $150.2M | $4.70 | $10.9M | $34.2M | 0.0% |
| Q2 2026 | 32.7M | $122.7M | $3.75 | −$30.4M | $2.85M | 0.0% |